Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
Jun 27, 2017

Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego

Jun 1, 2017

Oncolytics Biotech® Announces Closing of Public Offering of Units

May 24, 2017

Oncolytics Biotech® Prices Public Offering of Units

May 23, 2017

Oncolytics Biotech® Announces Proposed Public Offering

May 23, 2017

Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017

May 17, 2017

Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers

May 8, 2017

Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer

May 5, 2017

Oncolytics Biotech® Inc. Announces 2017 First Quarter Results

May 4, 2017

Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders

Apr 27, 2017

Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders

    • 1...
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • ...53
    © 2021 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap